Fig 2: Highly Conserved Mammalian lncRNA MORRBID/Morrbid Is Hyperactivated in Human and Murine Models of AML(A) Boxplot showing the expression levels of the MORRBID transcript in 150 normal whole-blood samples from the Genotype-Tissue Expression (GTEx) project compared against its expression in 175 AML samples from TCGA project. *p < 2.2e−16, Wilcoxon test.(B) Boxplot showing the expression levels of MORRBID in BM samples of AML patients with TET2 mutation (left) or WT TET2 (right) from TCGA gene expression data. y axis represents the log-normalized gene expression level. p = 0.048, Mann-Whitney test.(C) Overall survival of TET2 mutated patients with high/low expression of MORRBID. A significant integrative effect of high expression MORRBID and TET2 mutation in determining patient’s overall survival was observed compared to low expression of MORRBID. *p = 0.047.(D) Increased expression of MORRBID in AML cells with FLT3ITD mutation (FLT3ITD(+)) compared to AML cells without FLT3ITD mutation (FLT3ITD(−)). Mononuclear cells derived from AML patients negative for FLT3ITD (left) or positive for FLT3ITD (right) were subjected to qRT-PCR for MORRBID expression. n = 29 FLT3ITD(+) AML and 63 FLT3ITD(−) AML. **p < 0.01, Student’s t test.(E) Scatterplot of normalized gene expression level showing the top 1.1% percentile of MORRBID expression level among 20,134 genes and lncRNAs in nine bulk human AML stem cell samples.(F) Murine model of AML used in the present study. Flt3ITD/ITD mice (F) were bred with Tet2−/− mice (T) to generate Tet2−/−; Flt3ITD/ITD mice (TF).(G) Representative apoptosis profiles in myeloid cells (Mac1+) of WT and TF mice determined by Annexin-V staining (n = 4).(H) Expression of Morrbid and Bim in Lin− cells analyzed by qRT-PCR. **p < 0.01; ***p < 0.001.